Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-PV trial of ropeginterferon alfa-2b added to phlebotomy-based standard management in low-risk polycythemia vera
2015-004717-25Phase 2Completed
- Sponsor
- Fondazione per la Ricerca Ospedale di Bergamo
- Start
- May 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ropeginterferon alfa-2b in polycythemia vera (PV) (2 arms), sponsored by Fondazione per la Ricerca Ospedale di Bergamo. Primary endpoint: Primary efficacy endpoint. Started May 2017; status: completed.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on 2015-004717-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004717-25.